1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
SSY Group Limited

SSY Group Limited

LJUIF
SSY Group LimitedUS flagOther OTC
0.40
USD
- -
- -
1.19BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.59
0.71
0.76
0.83
1.08
1.4
1.53
1.41
1.77
2.16
2.18
1.95
- -
Basic EPS, GAAP
0.14
0.2
0.14
0.17
0.23
0.3
0.38
0.2
0.26
0.38
0.44
0.36
- -
Free Cash Flow per Basic Share
-0.11
-0.19
0.05
0.13
0.06
0.13
-0.06
0.06
0.1
0.11
0.07
-0.02
- -
Dividend per Share
0.04
0.08
0.2
0.03
0.06
0.08
0.1
0.11
0.1
0.13
0.15
0.18
- -
Book Value per Share
0.33
0.49
0.51
0.7
0.93
1.14
1.49
0.02
0.02
0.02
0.02
0.02
- -
Tangible Book Value per Share
0.87
0.99
0.69
0.8
1.04
1.3
1.53
1.73
1.85
1.84
2.06
2.12
- -
Basic Weighted Avg Shares
2,930
2,945
2,916
2,830
2,844
2,995
3,026
3,031
3,023
2,985
2,969
2,963
- -
Sales/Revenue/Turnover
1,723
2,091
2,222
2,361
3,076
4,181
4,636
4,261
5,357
6,434
6,463
5,773
4,165
Operating Margin (%)
27.39
29.52
24.32
27.1
27.73
26.52
27.04
17.6
18.03
22
25.19
23.28
14.02
Depreciation Expense
145
193
216
247
257
283
276
317
389
371
406
456
453
Net Income, GAAP
412
603
403
490
665
912
1,136
612
786
1,123
1,319
1,061
471
Effective Tax Rate (%)
16.5
15.27
15.65
16.61
16.76
15.25
16.44
15.77
16.88
14.98
16.06
16.07
14.23
Profit Margin (%)
23.9
28.83
18.16
20.73
21.61
21.81
24.51
14.36
14.66
17.45
20.4
18.38
11.3
Working Capital
196
533
199
584
1,011
1,708
1,788
2,141
2,490
2,207
2,603
3,240
2,337
LT Debt
455
364
1,125
935
848
1,046
880
1,105
1,691
1,562
1,951
2,982
2,245
Total Equity
2,867
3,253
2,395
2,684
3,487
4,378
5,187
5,915
6,493
6,546
7,269
7,536
7,621
Return on Invested Capital (%)
10.35
12.49
10.69
12.31
14.55
16.35
15.92
8.11
8.78
12.21
13.17
10.2
4.35
Return on Capital (%)
24.03
28.63
15.65
15.46
17.91
20.13
20.62
14.33
26.83
32.06
38.28
29.58
13.02
Return on Common Equity (%)
48.76
49.92
27.53
28.22
28.8
30.07
28.69
26.83
1,168.75
1,688.15
1,990.77
1,605.93
714.2

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.65%
5.28%
1.13%
Free Cash Flow
-89.28%
-157.66%
-706.91%
Net Income, GAAP
8.63%
2.71%
-55.65%
Sales/Revenue/Turnover
8.3%
1.55%
-27.85%
Total Cash Common Dividend
16.28%
6.76%
-20.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
6,463
2024
- -
- -
- -
- -
5,773
2025
- -
- -
- -
- -
4,165

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.44
2024
- -
- -
- -
- -
0.36
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.15
2024
- -
- -
- -
- -
0.18
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Jiguang Qu
Full Time Employees
6,146
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Central Plaza Wan Chai Hong Kong
IPO Date
Feb 25, 2015
Website
ssygroup.com.hk
Similar Companies
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
Bloomios, Inc. (BLMS)
Mangalam Drugs & Organics Limited (MANGALAM.NS)
The Green Organic Dutchman Holdings Ltd. (TGODD)
Cardiol Therapeutics Inc. (CRDL)
Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO)
Business
SSY Group Limited, formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd., is an investment holding company principally engaged in the research, development, manufacture, trading, and sale of a wide range of pharmaceutical products primarily to hospitals and distributors in the People's Republic of China and internationally; its core offerings include intravenous infusion solutions such as non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottle infusions, as well as ampoule injections, small volume injections, oral preparations, Chinese medicine preparations, biological preparations, bulk pharmaceutical products, and medical materials under the Shimen brand name. The company, founded in 1999 and headquartered in Wan Chai, Hong Kong, operates primarily through its Shijiazhuang No.4 Pharmaceutical production facilities, which feature advanced automated lines for green production of infusion solutions; it also engages in pharmaceutical technology research and consulting, logistics services for pharmaceutical products, and ancillary businesses including food, beverages, and catering. SSY Group Limited maintains leading positions in the intravenous infusion sector, with recent developments encompassing voluntary announcements on product development progress in December 2024, a framework agreement with Hightide Therapeutics, Inc. for joint research and development in December 2024, continuing connected transactions via master sale and purchase agreements as well as products manufacturing and transportation services agreements in December 2024, release of unaudited operating results for the first quarter ended March 2024, and ongoing advancements in bulk pharmaceuticals integrated with preparations to meet domestic market demands as highlighted in its 2025 interim results.